Tenofovir Alafenamide Fumarate (TAF) is an advanced nucleotide reverse transcriptase inhibitor that outperforms traditional Tenofovir Disoproxil Fumarate (TDF) with greater plasma stability and targeted delivery to the liver. Unlike TDF, TAF doesn’t accumulate in kidney cells, offering a safer profile for renal health. It combines potent antiviral effects with a high barrier to resistance, along with excellent bone and kidney safety. Recognized by leading hepatitis B treatment guidelines such as the China Medical Commission (CMC), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver (EASL), TAF is now a preferred first-line option for chronic hepatitis B therapy.